237
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation

, , , , , & show all
Pages 69-76 | Received 03 Oct 2022, Accepted 28 Dec 2022, Published online: 05 Jan 2023

References

  • Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–212. doi:10.1038/s41569-018-0119-4
  • Jimenez-Quevedo P, Serrador A, Perez de Prado A, et al. Spanish Cardiac Catheterization and Coronary Intervention Registry. 25th official report of the Spanish Society of Cardiology Working Group on cardiac catheterization and interventional cardiology (1990–2015). Rev Esp Cardiol. 2016;69(12):1180–1189. doi:10.1016/j.rec.2016.08.016
  • Peng N, Liu W, Li Z, et al. Drug-coated balloons versus everolimus-eluting stents in patients with in-stent restenosis: a pair-wise meta-analysis of randomized trials. Cardiovasc Ther. 2020;2020:1042329. doi:10.1155/2020/1042329
  • Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019;393(10190):2503–2510. doi:10.1016/S0140-6736(19)30474-X
  • Chang CF, Lin CC. Current concepts of contrast-induced nephropathy: a brief review. J Chin Med Assoc. 2013;76(12):673–681. doi:10.1016/j.jcma.2013.08.011
  • Sato A, Aonuma K, Watanabe M, et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: from the CINC-J study. Int J Cardiol. 2017;227:424–429. doi:10.1016/j.ijcard.2016.11.019
  • Huang FY, Huang BT, Pu XB, et al. CHADS(2), CHA(2)DS(2)-VASc and R(2)CHADS(2) scores predict mortality in patients with coronary artery disease. Intern Emerg Med. 2017;12(4):479–486. doi:10.1007/s11739-017-1608-x
  • Yao HM, Wan YD, Zhang XJ, et al. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open. 2014;4(8):e004892. doi:10.1136/bmjopen-2014-004892
  • Cooper HA, Domanski MJ, Rosenberg Y, et al. Acute ST-segment elevation myocardial infarction and prior stroke: an analysis from the Magnesium in Coronaries (MAGIC) trial. Am Heart J. 2004;148(6):1012–1019. doi:10.1016/j.ahj.2004.02.017
  • Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003;145(4):622–627. doi:10.1067/mhj.2003.6
  • Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–2353. doi:10.1001/archinte.163.19.2345
  • Kytö V, Sipilä J, Rautava P. Gender and in-hospital mortality of ST-segment elevation myocardial infarction (from a multihospital nationwide registry study of 31,689 patients). Am J Cardiol. 2015;115(3):303–306. doi:10.1016/j.amjcard.2014.11.001
  • Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–2037. doi:10.1161/01.CIR.102.17.2031
  • Kirigaya H, Kato S, Gyotoku D, et al. Higher CHADS2 score is associated with impaired coronary flow reserve: a study using phase contrast cine magnetic resonance imaging. Int J Cardiol. 2016;221:800–805. doi:10.1016/j.ijcard.2016.07.116
  • Hsu PC, Chiu CA, Chu CY, et al. CHADS2 score and risk of new-onset peripheral arterial occlusive disease in patients without atrial fibrillation: a Nationwide Cohort Study in Taiwan. J Atheroscler Thromb. 2015;22(5):490–498. doi:10.5551/jat.27284
  • Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314(10):1030–1038. doi:10.1001/jama.2015.10725
  • Alraies MC, Darmoch F, Tummala R, et al. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol. 2017;9(8):640–651. doi:10.4330/wjc.v9.i8.640
  • Alfonso F, Díez-Villanueva P, Rivero F. CHA(2)DS(2)-VAS(C) clinical score to predict in-stent restenosis. Angiology. 2018;69(8):653–656. doi:10.1177/0003319717736159
  • Rampidis GP, Benetos G, Benz DC, et al. A guide for gensini score calculation. Atherosclerosis. 2019;287:181–183. doi:10.1016/j.atherosclerosis.2019.05.012
  • Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi:10.1378/chest.09-1584
  • Mazzone C, Cioffi G, Carriere C, et al. Predictive role of CHA(2)DS(2)-VASc score for cardiovascular events and death in patients with arterial hypertension and stable sinus rhythm. Eur J Prev Cardiol. 2017;24(15):1584–1593. doi:10.1177/2047487317726068
  • Soylemez N, Balli M, Koksal F, et al. A new current to the armamentarium: is the CHA2DS2-Vasc-HS score predictive of low left internal mammary artery (lima) flow in patients underwent coronary bypass surgery? Heart Surg Forum. 2021;24(4):E631–E636. doi:10.1532/hsf.3837
  • Rozenbaum Z, Elis A, Shuvy M, et al. CHA2DS2-VASc score and clinical outcomes of patients with acute coronary syndrome. Eur J Intern Med. 2016;36:57–61. doi:10.1016/j.ejim.2016.09.010
  • Maden O, Çakmak Karaaslan Ö, Kanal Y, et al. Association of CHA2DS2-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI. Herz. 2022;47(5):456–464. doi:10.1007/s00059-021-05070-x
  • Kim KH, Kim W, Hwang SH, et al. The CHA2DS2VASc score can be used to stratify the prognosis of acute myocardial infarction patients irrespective of presence of atrial fibrillation. J Cardiol. 2015;65(2):121–127. doi:10.1016/j.jjcc.2014.04.011
  • Ünal S, Açar B, Yayla Ç, et al. Importance and usage of the CHA2DS2-VASc score in predicting acute stent thrombosis. Coron Artery Dis. 2016;27(6):478–482. doi:10.1097/MCA.0000000000000388
  • Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907. doi:10.1016/j.jacc.2010.07.028
  • Lee MS, Banka G. In-stent Restenosis. Interv Cardiol Clin. 2016;5(2):211–220. doi:10.1016/j.iccl.2015.12.006
  • Shehadeh N, Raz I, Nakhleh A. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):117. doi:10.1186/s12933-018-0760-6
  • Luo Y, Cui S, Zhang C, et al. Prognostic role of fasting remnant cholesterol with in-stent restenosis after drug-eluting stent implantation. Int J Gen Med. 2022;15:1733–1742. doi:10.2147/IJGM.S348148